The CEO of the Saudi Food and Drug Authority (SFDA), Dr. Hisham S. Aljadhey, has introduced the Saudi Pharmacopoeia at the Global Health Exhibition in Riyadh (Held from October 27 to 30), marking a significant milestone in the nation’s pharmaceutical sector.

The new Pharmacopoeia establishes an official reference for the quality, formulation, and analysis standards of medicines and vaccines available in the Kingdom. Particularly, it includes a dedicated “Halal” chapter, which can act as a “regulatory example among global pharmacopoeias”, demonstrating Saudi Arabia’s commitment to aligning regulatory standards with Islamic Sharia and enhancing confidence in both regional and global markets.

Dr. Aljadhey highlighted the Saudi Pharmacopoeia’s essential role supporting the national pharmaceutical industry by offering distinctive benchmarks for quality and testing, thereby supporting regulatory compliance, localization, and innovation. The initiative is also designed to attract foreign investment and increase consumer trust in Saudi pharmaceutical products. The reference serves not only manufacturers but also regulators and researchers, contributing to drug safety, product excellence, and the growth of human capacity within the sector.

By taking this step, the SFDA continues to promote the Kingdom’s leadership in medicine and supports the Saudi Vision 2030 Health Sector Transformation objectives. Also, the launch at the Global Health Exhibition -a major platform for healthcare leaders and innovators- emphasizes the Kingdom’s ongoing commitment to global health, quality, and innovation.

Learn more: SFDA CEO Launches the Saudi Pharmacopoeia on the Sidelines of the Global Health Exhibition